rabeprazole has been researched along with Benign Neoplasms in 5 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment." | 1.37 | E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. ( Bello, E; Berndt, A; Camboni, G; Cavalletti, E; Colella, G; D'Incalci, M; Damia, G; Giavazzi, R; Oliva, P; Scarlato, V; Serra, SC; Valbusa, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bello, E | 1 |
| Colella, G | 1 |
| Scarlato, V | 1 |
| Oliva, P | 1 |
| Berndt, A | 1 |
| Valbusa, G | 1 |
| Serra, SC | 1 |
| D'Incalci, M | 2 |
| Cavalletti, E | 1 |
| Giavazzi, R | 1 |
| Damia, G | 1 |
| Camboni, G | 1 |
| Sala, F | 1 |
| Bagnati, R | 1 |
| Livi, V | 1 |
| Cereda, R | 1 |
| Zucchetti, M | 1 |
| Domeki, Y | 1 |
| Yamazaki, E | 1 |
| Matsuura, A | 1 |
| Kitajima, K | 1 |
| Murakami, K | 1 |
| Kato, H | 1 |
| Miao, ZH | 1 |
| Feng, JM | 1 |
| Ding, J | 1 |
| Sheptulin, AA | 1 |
2 reviews available for rabeprazole and Benign Neoplasms
| Article | Year |
|---|---|
Newly discovered angiogenesis inhibitors and their mechanisms of action.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Diterpenes; Drug Design; Drug Resistance, N | 2012 |
[Safety profile of pariet clinical use (a literature review)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; | 2001 |
2 trials available for rabeprazole and Benign Neoplasms
| Article | Year |
|---|---|
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study.
Topics: Angiogenesis Inhibitors; Calibration; Chromatography, High Pressure Liquid; Humans; Limit of Detecti | 2011 |
Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Colon; Drug Administration | 2012 |
1 other study available for rabeprazole and Benign Neoplasms
| Article | Year |
|---|---|
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antineoplastic Agents; Cells, Cultured; Drug Evalu | 2011 |